POAI (Predictive Oncology) Net Profit

Official company branding of predictive-oncology.com (POAI)

Predictive Oncology is implementing robotics for cancer therapy analysis, replacing traditional tests with computer modeling. Primary revenue is generated through B2B subscriptions to the PeDAL platform, which accelerates the discovery of oncology drugs. The company's profit history confirms financial stability, where -0.09 serves as the current metric level. The scaling of cloud data archives is delegated to IT partners, eliminating the business's infrastructure dependency.

POAI: Predictive Oncology Corp Net Income 07/04/2022 - 12/12/2025

Analytical breakdowns and data insights for company predictive-oncology.com (POAI)

- price and consensus price forecast:
Stock Quotes Predictive Oncology Inc.|POAI - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization POAI|POAI - Total Company Value
- book capitalization data:
Net Assets per Single Share Predictive Oncology|POAI - Company Net Assets|Market Value to Book Value predictive-oncology.com|POAI - Company Total Assets
- debt and liquidity details:
Total Debt to Capital Coefficient Predictive Oncology|POAI - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Predictive Oncology Inc.|POAI - Company Debts|Debts to Net Assets POAI|POAI - Company Long-Term Liabilities|Amount of Current Liabilities Predictive Oncology|Intermediate Coverage Ratio predictive-oncology.com
- earnings and valuation multiples information:
POAI - Net Income
Basic company analysis:POAI - Predictive Oncology Corp
Mass-produced product of Predictive Oncology Corp

Predictive Oncology (POAI) high dependence on external medical providers and AWS cloud infrastructure makes its financial results sensitive to vendor operational risks. When analyzing the company's bottom line, investors assess net operating efficiency and the business's market value, where sharp spikes in this indicator may signal temporary anomalies that require caution when determining a fair fundamental valuation of capital.

Key competitors

Net Income Intuitive Corp|DHR (Danaher Corp.) - Net Profit|Net Profit bd.com|Company Net Income STERIS (STE)|Company Net Income WST (West Pharma)|Baxter Corp - Net Income|Final Profit MASI|Stevanato Group S.p.A. - Net Profit|Net Financial Result teleflex.com TFX|Merit Medical (MMSI) - Company Net Income|Company Profit NVST|Company Net Income ICU Medical Corp|Sirona Dental Systems (XRAY) - Net Financial Result|Net Income LMAT (LeMaitre Vascular, Inc.)|Profit After Payment of Taxes ATRC|Company Net Income STAAR Surgical STAA|Final Profit NAGE|ZIMV: Net Income|ANGO - Net Profit|Cerus Corporation (CERS) - Company Net Income|Net Income teknova.com|MGRM (Monogram Orthopedics) - Net Profit|Company Net Income Sharps Tech STSS|Company Net Income InfuSystem Holdings (INFU)|Utah Med - Company Profit|KORU Medical - Net Income|Profit After Payment of Taxes NYXH (nyxoah.com)|MBOT - Company Net Income|Net Financial Result Pro-Dex Inc PDEX|Zentek Limited (ZTEK) - Company Net Income|Profit After Tax ELUT (Elutia Corporation)|Company Net Income Milestone Scientific|NXGL: Final Profit|Net Profit RVP|HBIO - Company Net Income|Net Profit FEMY (Femasys Corp)|MHUA: Company Profit|Callan JMB Corp - Net Profit|Net Financial Result atrioncorp.com ATRI|NURO: Net Profit